Product Program year 2021 Source: CMS Open Payments

Revatio

Drug Genitourinary (Sexual Health);Cardiovascular;Respiratory

NDC 0069-0338-01

Open in the dashboard

General payments

$4,932

13 payments

Research payments

$521,129

54 payments

Through program year 2021, $4,932 in general payments and $521,129 in research payments were reported against Revatio (Genitourinary (Sexual Health);Cardiovascular;Respiratory).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2021 Research $19,416 4
2020 Research $52,678 29
2019 General $4,932 13
2019 Research $449,034 21

Breakdown

Who paid General payments · program year 2019
  1. Pfizer Inc. $4,932 13 payments
Top recipients General payments · program year 2019
  1. David Cornfield Pediatric Pulmonology · Palo Alto, CA $1,720 35% · 4 payments
  2. Matthew Laughon Pediatrics · Chapel Hill, NC $1,571 32% · 4 payments
  3. Steven Abman Pediatric Pulmonology · Aurora, CO $1,266 26% · 4 payments
  4. Robin Steinhorn Neonatal-Perinatal Medicine · Sacramento, CA $374 8% · 1 payment

Each share is of general payments naming this product in 2019.

Specialties paid General payments · program year 2019
  1. Pediatric Pulmonology Pediatrics $2,986 61% · 2 practitioners
  2. Pediatrics $1,571 32% · 1 practitioner
  3. Neonatal-Perinatal Medicine Pediatrics $374 8% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2019
  1. California $1,720 35% · 1 recipient
  2. North Carolina $1,571 32% · 1 recipient
  3. Colorado $1,266 26% · 1 recipient
  4. District of Columbia $374 8% · 1 recipient

Each share is of general payments naming this product in 2019 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

361

Prescriptions dispensed, refills included

Drug cost

$2,833,559

Paid at the pharmacy, in all

Prescribers

25

With 11 or more claims of it

Medicare Part D drugs matched to REVATIO, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Revatio Sildenafil Citrate Same name 25 361 $2,833,559

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 25 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Juliana Liu Nurse Practitioner CA 28 $208,635 None on record
Vallerie McLaughlin Cardiology MI 24 $333,139 None on record
Jennalyn Mayeux Nurse Practitioner UT 23 $126,592 None on record
Barry Cabuay Cardiology MN 22 $284,073 None on record
Hilamber Subba Internal Medicine ME 20 $335,979 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See all 25 in the dashboard with a free account
13 general · 54 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record